{"title_page": "Altropane", "text_new": "{{Drugbox\n| Watchedfields = changed\n| verifiedrevid = 449574326\n| IUPAC_name = Methyl (1''R'',2''S'',3''S'',5''S'')-3-(4-fluorophenyl)-8-[(''E'')-3-iodoprop-2-enyl]-8-azabicyclo[3.2.1]octane-2-carboxylate\n| image = Altropane.svg\n| width = 220\n\n<!--Clinical data-->\n| tradename =  \n| routes_of_administration =  \n\n<!--Identifiers-->\n| CAS_number_Ref = {{cascite|correct|??}}\n| CAS_number = 180468-34-2\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = 1Q4092099O\n| ATC_prefix = none\n| ATC_suffix =  \n| PubChem = 6440180\n| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}\n| ChemSpiderID = 4944487\n\n<!--Chemical data-->\n| C=18 | H=21 | F=1 | I=1 | N=1 | O=2 \n| molecular_weight = 429.2694\n| smiles = COC(=O)[C@@H]1[C@H]2CC[C@H](N2C\\C=C\\I)C[C@@H]1C3=CC=C(C=C3)F\n| StdInChI_Ref = {{stdinchicite|correct|chemspider}}\n| StdInChI = 1S/C18H21FINO2/c1-23-18(22)17-15(12-3-5-13(19)6-4-12)11-14-7-8-16(17)21(14)10-2-9-20/h2-6,9,14-17H,7-8,10-11H2,1H3/b9-2+/t14-,15+,16+,17-/m0/s1\n| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}\n| StdInChIKey = GTQLIPQFXVKRKJ-UNSMHXHVSA-N\n}}\n\n'''Altropane''', ('''O-587''', '''IACFT''', '''2\u03b2-carbomethoxy-3\u03b2-(4-fluorophenyl)-''N''-((E)-3-iodo-prop-2-enyl)tropane''') is a [[phenyltropane]] derivative which acts as a potent [[dopamine reuptake inhibitor]] and long-acting [[stimulant]] drug. It has mainly been used as the <sup>125</sup>I [[isotopic labelling|radiolabelled]] form for mapping the distribution of [[dopamine transporter]]s in the brain,<ref>{{cite journal | vauthors = Elmaleh DR, Fischman AJ, Shoup TM, Byon C, Hanson RN, Liang AY, Meltzer PC, Madras BK | display-authors = 6 | title = Preparation and biological evaluation of iodine-125-IACFT: a selective SPECT agent for imaging dopamine transporter sites | journal = Journal of Nuclear Medicine | volume = 37 | issue = 7 | pages = 1197\u2013202 | date = July 1996 | pmid = 8965198 }}</ref> and consequently this has led to its development as a potential diagnostic tool for early detection of [[Parkinson's disease]].<ref>{{cite journal | vauthors = Fischman AJ, Bonab AA, Babich JW, Palmer EP, Alpert NM, Elmaleh DR, Callahan RJ, Barrow SA, Graham W, Meltzer PC, Hanson RN, Madras BK | display-authors = 6 | title = Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters | journal = Synapse | volume = 29 | issue = 2 | pages = 128\u201341 | date = June 1998 | pmid = 9593103 | doi = 10.1002/(SICI)1098-2396(199806)29:2<128::AID-SYN4>3.0.CO;2-9 }}</ref> It is also being investigated for potential use in the diagnosis and treatment of [[attention deficit hyperactivity disorder]] (ADHD).<ref>{{cite journal | vauthors = Cattabeni F | title = Altropane (Boston Life Science) | journal = Current Opinion in Investigational Drugs | volume = 3 | issue = 11 | pages = 1647\u201351 | date = November 2002 | pmid = 12476968 }}</ref><ref>{{cite journal | vauthors = Spencer TJ, Biederman J, Madras BK, Dougherty DD, Bonab AA, Livni E, Meltzer PC, Martin J, Rauch S, Fischman AJ | display-authors = 6 | title = Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane | journal = Biological Psychiatry | volume = 62 | issue = 9 | pages = 1059\u201361 | date = November 2007 | pmid = 17511972 | doi = 10.1016/j.biopsych.2006.12.008 | pmc = 2715944 }}</ref>\n\n== References ==\n{{Reflist}}\n\n{{Stimulants}}\n{{Monoamine reuptake inhibitors}}\n{{Phenyltropanes}}\n\n[[Category:Tropanes]]\n[[Category:Dopamine reuptake inhibitors]]\n[[Category:Medical imaging]]\n[[Category:Neuroimaging]]\n[[Category:Organoiodides]]\n\n{{nervous-system-drug-stub}}\n", "text_old": "{{Drugbox\n| Watchedfields = changed\n| verifiedrevid = 449574326\n| IUPAC_name = Methyl (1''R'',2''S'',3''S'',5''S'')-3-(4-fluorophenyl)-8-[(''E'')-3-iodoprop-2-enyl]-8-azabicyclo[3.2.1]octane-2-carboxylate\n| image = Altropane.svg\n| width = 220\n\n<!--Clinical data-->\n| tradename =  \n| routes_of_administration =  \n\n<!--Identifiers-->\n| CAS_number_Ref = {{cascite|correct|??}}\n| CAS_number = 180468-34-2\n| ATC_prefix = none\n| ATC_suffix =  \n| PubChem = 6440180\n| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}\n| ChemSpiderID = 4944487\n\n<!--Chemical data-->\n| C=18 | H=21 | F=1 | I=1 | N=1 | O=2 \n| molecular_weight = 429.2694\n| smiles = COC(=O)[C@@H]1[C@H]2CC[C@H](N2C\\C=C\\I)C[C@@H]1C3=CC=C(C=C3)F\n| StdInChI_Ref = {{stdinchicite|correct|chemspider}}\n| StdInChI = 1S/C18H21FINO2/c1-23-18(22)17-15(12-3-5-13(19)6-4-12)11-14-7-8-16(17)21(14)10-2-9-20/h2-6,9,14-17H,7-8,10-11H2,1H3/b9-2+/t14-,15+,16+,17-/m0/s1\n| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}\n| StdInChIKey = GTQLIPQFXVKRKJ-UNSMHXHVSA-N\n}}\n\n'''Altropane''', ('''O-587''', '''IACFT''', '''2\u03b2-carbomethoxy-3\u03b2-(4-fluorophenyl)-''N''-((E)-3-iodo-prop-2-enyl)tropane''') is a [[phenyltropane]] derivative which acts as a potent [[dopamine reuptake inhibitor]] and long-acting [[stimulant]] drug. It has mainly been used as the <sup>125</sup>I [[isotopic labelling|radiolabelled]] form for mapping the distribution of [[dopamine transporter]]s in the brain,<ref>{{cite journal | vauthors = Elmaleh DR, Fischman AJ, Shoup TM, Byon C, Hanson RN, Liang AY, Meltzer PC, Madras BK | display-authors = 6 | title = Preparation and biological evaluation of iodine-125-IACFT: a selective SPECT agent for imaging dopamine transporter sites | journal = Journal of Nuclear Medicine | volume = 37 | issue = 7 | pages = 1197\u2013202 | date = July 1996 | pmid = 8965198 }}</ref> and consequently this has led to its development as a potential diagnostic tool for early detection of [[Parkinson's disease]].<ref>{{cite journal | vauthors = Fischman AJ, Bonab AA, Babich JW, Palmer EP, Alpert NM, Elmaleh DR, Callahan RJ, Barrow SA, Graham W, Meltzer PC, Hanson RN, Madras BK | display-authors = 6 | title = Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters | journal = Synapse | volume = 29 | issue = 2 | pages = 128\u201341 | date = June 1998 | pmid = 9593103 | doi = 10.1002/(SICI)1098-2396(199806)29:2<128::AID-SYN4>3.0.CO;2-9 }}</ref> It is also being investigated for potential use in the diagnosis and treatment of [[attention deficit hyperactivity disorder]] (ADHD).<ref>{{cite journal | vauthors = Cattabeni F | title = Altropane (Boston Life Science) | journal = Current Opinion in Investigational Drugs | volume = 3 | issue = 11 | pages = 1647\u201351 | date = November 2002 | pmid = 12476968 }}</ref><ref>{{cite journal | vauthors = Spencer TJ, Biederman J, Madras BK, Dougherty DD, Bonab AA, Livni E, Meltzer PC, Martin J, Rauch S, Fischman AJ | display-authors = 6 | title = Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane | journal = Biological Psychiatry | volume = 62 | issue = 9 | pages = 1059\u201361 | date = November 2007 | pmid = 17511972 | doi = 10.1016/j.biopsych.2006.12.008 | pmc = 2715944 }}</ref>\n\n== References ==\n{{Reflist}}\n\n{{Stimulants}}\n{{Monoamine reuptake inhibitors}}\n{{Phenyltropanes}}\n\n[[Category:Tropanes]]\n[[Category:Dopamine reuptake inhibitors]]\n[[Category:Medical imaging]]\n[[Category:Neuroimaging]]\n[[Category:Organoiodides]]\n\n{{nervous-system-drug-stub}}\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/Altropane"}
